Chemoinformaics analysis of 1,5-Dioxo-2,3-Dihydroxyrhamnofola4(10)
| Molecular Weight | 328.408 | nRot | 1 |
| Heavy Atom Molecular Weight | 304.216 | nRig | 19 |
| Exact Molecular Weight | 328.167 | nRing | 3 |
| Solubility: LogS | -3.746 | nHRing | 0 |
| Solubility: LogP | 2.603 | No. of Aliphatic Rings | 3 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 3 |
| Atoms Count | 48 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 24 | No. of Aromatic Carbocycles | 0 |
| nHetero | 4 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 1 |
| No. of Hydrogen atom | 24 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 20 | No. of Saturated Rings | 1 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 4 | No. of Arom Bond | 0 |
| nHA | 4 | APOL | 52.611 |
| nHD | 2 | BPOL | 25.813 |
| QED | 0.777 |
| Synth | 4.64 |
| Natural Product Likeliness | 1.673 |
| NR-PPAR-gamma | 0.542 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0.016 |
| Pgp-sub | 0.325 |
| HIA | 0.008 |
| CACO-2 | -4.661 |
| MDCK | 0.0000124 |
| BBB | 0.638 |
| PPB | 0.893656 |
| VDSS | 2.005 |
| FU | 0.0672267 |
| CYP1A2-inh | 0.065 |
| CYP1A2-sub | 0.798 |
| CYP2c19-inh | 0.059 |
| CYP2c19-sub | 0.88 |
| CYP2c9-inh | 0.068 |
| CYP2c9-sub | 0.596 |
| CYP2d6-inh | 0.011 |
| CYP2d6-sub | 0.168 |
| CYP3a4-inh | 0.418 |
| CYP3a4-sub | 0.646 |
| CL | 1.857 |
| T12 | 0.025 |
| hERG | 0.024 |
| Ames | 0.098 |
| ROA | 0.303 |
| SkinSen | 0.052 |
| Carcinogencity | 0.041 |
| EI | 0.015 |
| Respiratory | 0.735 |
| NR-Aromatase | 0.927 |
| Antiviral | No |
| Prediction | 0.602621 |